Biliary Tract Cancer (BTC) Patient Pool Analysis and Epidemiology Forecast APAC - 2036

Key Highlights:

• Biliary tract cancer (BTC) is a group of rare but highly aggressive malignancies arising from the epithelial lining of the biliary system, including Gall Bladder Cancer (GBC), intrahepatic cholangiocarcinoma (iCCA), extrahepatic cholangiocarcinoma (eCCA), and cancer of the ampulla of Vater.
• The global incidence of BTC shows marked geographic variation, with higher rates observed in East Asia and parts of Latin America, while incidence remains comparatively lower in Western countries. GBC demonstrates a distinct female predominance, largely attributed to the higher prevalence of gallstone disease among women, whereas cholangiocarcinoma subtypes generally show male predominance. Incidence rates for iCCA have shown a consistent upward trend in several regions, reflecting improved diagnostic accuracy as well as changing risk factor profiles.
• In China, gallbladder cancer shows a significantly higher incidence in females, while intrahepatic and extrahepatic cholangiocarcinoma are more commonly observed in males.
• Despite accounting for 59.05% of the global population, Asia represents a disproportionately high 71.9% share of the global incidence of biliary tract cancers.
• In Australia, Cholangiocarcinoma is slightly more prevalent in males and is predominantly diagnosed in patients aged over 70 years.

DelveInsight's 'Biliary Tract Cancer (BTC) -Epidemiology Forecast - 2036' report delivers an in-depth understanding of the Biliary Tract Cancer (BTC), historical and forecasted epidemiology in the APAC region (India, China, South Korea, Taiwan, and Australia)

Biliary Tract Cancer (BTC) Understanding and Diagnosis

Biliary Tract Cancer (BTC) Overview

BTC is a heterogeneous group of rare and aggressive malignancies arising from the epithelial lining of the biliary system, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer. These cancers are often diagnosed at advanced stages due to nonspecific symptoms and limited early detection strategies. Prognosis remains poor, particularly for advanced disease, with limited curative options outside of early surgical resection. Further, advances in molecular profiling have led to the emergence of targeted therapies and immunotherapies, improving outcomes for selected patient subgroups.

Diagnosis

Diagnosis of BTC is often challenging due to nonspecific clinical symptoms such as jaundice, abdominal pain, weight loss, and pruritus. Initial evaluation typically includes liver function tests and tumor markers such as CA 19-9, although these lack specificity. Imaging modalities, including ultrasound, contrast-enhanced CT, and MRI/Magnetic Resonance Cholangiopancreatography (MRCP), are central to detecting tumors, defining anatomical extent, and assessing resectability. Endoscopic procedures such as Endoscopic Retrograde Cholangiopancreatography (ERCP) or Endoscopic Ultrasound (EUS) may be used for tissue sampling and biliary drainage. Histopathological confirmation is required for definitive diagnosis, and molecular testing is increasingly performed to identify actionable genetic alterations that guide targeted therapy selection.

Biliary Tract Cancer (BTC) Epidemiology

Key Findings from BTC Epidemiological Analysis and Forecast

• Among BTCs, gallbladder cancer is one of the most aggressive and lethal subtypes, representing approximately 1.3% of overall global cancer incidence. India accounts for nearly 10% of the global gallbladder cancer burden.
• In China, the disease burden of gallbladder and biliary tract cancer (GBTC) is higher in males than in females, with incidence rates increasing significantly in older age groups.
• In 2025, intrahepatic cholangiocarcinoma (ICC) in South Korea demonstrated lower frequencies of IDH1 mutations and FGFR2 fusions, whereas gallbladder cancer exhibited a comparatively higher prevalence of ERBB2 (HER2) amplification.
• TP53 is the most frequently mutated gene in BTCs, followed by KRAS, ARID1A, IDH1, and PIK3CA. TP53 mutations were prevalent across both gallbladder cancer and cholangiocarcinoma, while IDH1 mutations were predominantly associated with cholangiocarcinoma.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of BTC, explaining their causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• Biliary Tract Cancer (BTC) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• 11-year forecast

FAQs:

• What are the disease risks, burdens, and unmet needs of BTC? What will be the growth opportunities across the APAC market concerning the patient population with BTC?
• What is the historical and forecasted BTC patient pool in the APAC region (India, China, South Korea, Taiwan, and Australia)?

Reasons to Buy:

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders' perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.